Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Postmarketing Observational Cohort Study to Evaluate Effectiveness and Safety of Ponatinib (Iclusig®) in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

NCT03515785 is registered in ClinicalTrials.gov with Incyte Biosciences International Sàrl as lead sponsor.

NCT NCT03515785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03515785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Postmarketing Observational Cohort Study to Evaluate Effectiveness and Safety of Ponatinib (Iclusig®) in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"
Lead sponsor
Incyte Biosciences International Sàrl
Phase
Observational
Overall status
Withdrawn
Start date
December 31, 2018
Completion date
March 31, 2021
Enrollment
0 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

bcr-abl positive acute lymphoblastic leukemia